NanoViricides is trading 5.6% up at $1.50 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week in Ituri province, Democratic Republic of Congo.
- The trial is expected to dose patients at an Ebola Treatment Center, subject to outbreak-related impediments.
- The catalyst follows a 16.67% regular-session gain on September 17, 2026, extending the recent rally.
- The broader market’s positive September 17 session may have provided additional support; coverage remains limited, so confidence is medium.